<DOC>
	<DOCNO>NCT01269580</DOCNO>
	<brief_summary>Type Study : Pilot Study monocenter Study Duration : 18 month Subject Participation Duration : The patient enrol time blood withdrawl . Follow visit 12 month enrollement . Objectives : The project two major objective : A ) To validate prognostic value vascular progenitor cell , identify flow cytometric analysis antigenic phenotype , cohort 109 patient type-2 diabetes complicate ischemic foot ulcer . Events : cardiovascular mortality , major amputation , post-angioplasty restenosis , development new atherosclerotic plaque treat limb B ) To determine mechanism responsible vascular progenitor cell dysfunction perspective new therapy cure diabetic foot .</brief_summary>
	<brief_title>Diabetic Foot Vascular Progenitor Cells</brief_title>
	<detailed_description>This collaborative project aim produce significant output identification patient require intensification therapy . Furthermore , project fill gap current knowledge post-genomic alteration render diabetic vascular progenitor cell dysfunctional . In perspective , might help u design new therapy cure diabetic foot , include limited stem cell therapy . Primary Objectives : To validate prognostic value vascular progenitor cell , identify flow cytometric analysis antigenic phenotype , cohort 109 patient type-2 diabetes complicate ischemic foot ulcer . Events : Cardiovascular mortality Major amputation Post-angioplasty restenosis Development new atherosclerotic plaque treat limb ( follow : 12 month ) . Secondary Objectives : To determine mechanism responsible vascular progenitor cell dysfunction perspective new therapy cure diabetic foot . All Units contribute primary objective ( validate prognostic value vascular progenitor cell , identify flow cytometric analysis antigenic phenotype , cohort 100 patient type-2 diabetes complicate ischemic foot ulcer ) . Furthermore , Unit focus specific mechanistic target , accord pilot data collect previous ongoing project . Dr Faglia , Head Diabetology Unit , Diabetic Foot Centre ( IRCCS Multimedica-MM ) , conduct selection enrollement patient , collect clinical data study 12 month follow visit . The Unit lead Prof. Madeddu ( IRCCS Multimedica ) , perform antigenic characterization vascular progenitor cell flow cytometry , conduct migration assay . The Unit lead Prof. Madeddu ( IRCCS Multimedica ) Unit lead Dr. Gaetano Martelli ( IDI , Rome ) engage determine whether vascular progenitor cell dysfunction mediate specific epigenetic modification . Epigenetics refers covalent modification find chromatin , DNA accompany histone protein . The Unit Dr. Germani ( IDI , Rome ) focus identification growth factor , chemokines cytokine serum diabetic patient could involve deregulation progenitor function . Since normal criterion already available , conduct analysis perform UO IDI , need enrol group 30 not-diabetic subject age- sex-matched identify key change analyze entire group patient . Thirty patient come MM , UO Vascular Surgery , Dr Losa , varicose vein treatment carotid stenosis enrol subject blood withdrawal describe diabetic patient group . Subject Inclusion Criteria : Adult diabetic patient type 1 2 , men woman , chronic critical ischemia define TASC 2007 criterion ( pain rest , and/or ulcer gangrene due artheropaty : transcutaneous oximetry &lt; 30 mmHg pressure ankle &lt; 70 mmHg ) . Subject Exclusion Criteria : - Cancer adverse prognosis month , chemotherapic treatment - Ongoing planned pregnancy - Lack consent participate study Patients enrolment At time patient undergo follow exam : - General comprehensive visit ( include : Chest RX , Rest ECG , glycaemia plus glycosilated haemoglobin measurement ) - Ankle arterial pressure ( Doppler cw measurement ) - Angiographyc study angioplasty , feasible , time IMPORTANT NOTE : At enrolment visit follow visit 12 month perform : - Ecodoppler - Transcutaneous oximetry - Completion antigenic profile - Assessment migratory capacity - Characterization major epigenetic signature - Paracrine profiling</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>Adult diabetic patient type 1 2 Chronic critical ischemia define TASC 2007 criterion ( pain rest , and/or ulcer gangrene due artheropaty : transcutaneous oximetry &lt; 30 mmHg pressure ankle &lt; 70 mmHg ) Cancer adverse prognosis month , chemotherapic treatment Ongoing plan pregnancy Lack consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>